Literature DB >> 1352252

Persistent supersensitivity of sigma receptors develops during repeated methamphetamine treatment.

H Ujike1, K Okumura, Y Zushi, K Akiyama, S Otsuki.   

Abstract

Functional changes in sigma receptors were examined after behavioral sensitization induced by repeated methamphetamine treatment. Rats received either saline or 4 mg/kg methamphetamine for 14 days. (+)3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP), a sigma receptor agonist, was given as challenge after various periods of abstinence. (+)-3-PPP at doses greater than 6 mg/kg stimulated several forms of behavior in naive rats. (+)-3-PPP at 12 and 24 mg/kg produced more frequent rearing and more intense stereotyped sniffing and repetitive head movements in rats previously sensitized with methamphetamine than in saline-pretreated rats. The augmented response to (+)-3-PPP in methamphetamine-treated rats was maintained for at least one month. The augmented response to (+)-3-PPP was reversed by the combined administration of 100 mg/kg (+/-)-sulpiride, a D2 dopamine receptor antagonist, and 30 mg/kg BMY 14802, a sigma receptor antagonist. These results suggest that repeated methamphetamine treatment induces persistent supersensitivity in sigma receptors and that it may subsequently activate the dopamine system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352252     DOI: 10.1016/0014-2999(92)90388-k

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

2.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 3.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

4.  Targeting sigma receptors: novel medication development for drug abuse and addiction.

Authors:  Rae R Matsumoto
Journal:  Expert Rev Clin Pharmacol       Date:  2009-07       Impact factor: 5.045

5.  Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine.

Authors:  Michael J Seminerio; Matthew J Robson; Ahmed H Abdelazeem; Christophe Mesangeau; Seshulatha Jamalapuram; Bonnie A Avery; Christopher R McCurdy; Rae R Matsumoto
Journal:  AAPS J       Date:  2011-12-20       Impact factor: 4.009

Review 6.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Interactions between 3,4-methylenedioxymethamphetamine and sigma1 receptors.

Authors:  Matthew K Brammer; Deborah L Gilmore; Rae R Matsumoto
Journal:  Eur J Pharmacol       Date:  2006-09-28       Impact factor: 4.432

8.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

9.  Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats.

Authors:  Teruo Hayashi; Zuzana Justinova; Eri Hayashi; Gianfrancesco Cormaci; Tomohisa Mori; Shang-Yi Tsai; Chanel Barnes; Steven R Goldberg; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

10.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.